Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods for inhibiting atherosclerosis by administering an inhibitor of pcsk9

a technology of atherosclerosis and inhibitors, which is applied in the field of proproteins, can solve the problems that pcsk9 inhibitors have not been reported to reduce or inhibit the progression of atherosclerotic plaque formation, and achieve the effect of reducing atherosclerotic plaque formation

Inactive Publication Date: 2018-08-30
REGENERON PHARM INC
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0015]In another embodiment, the PCSK9 inhibitor reduces atherosclerotic plaque formation in the subject by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90%.

Problems solved by technology

Nonetheless, PCSK9 inhibitors have not been reported to reduce or inhibit progression of atherosclerotic plaque formation in a subject.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods for inhibiting atherosclerosis by administering an inhibitor of pcsk9
  • Methods for inhibiting atherosclerosis by administering an inhibitor of pcsk9
  • Methods for inhibiting atherosclerosis by administering an inhibitor of pcsk9

Examples

Experimental program
Comparison scheme
Effect test

example 1

Generation of Human Antibodies to Human PCSK9

[0133]Human anti-PCSK9 antibodies were generated as described in U.S. Pat. No. 8,062,640. The exemplary PCSK9 inhibitor used in the following Example is the human anti-PCSK9 antibody designated “mAb316P,” also known here as “alirocumab.” mAb316P has the following amino acid sequence characteristics: heavy chain variable region (HCVR) comprising SEQ ID NO:1; light chain variable domain (LCVR) comprising SEQ ID NO:6; heavy chain complementarity determining region 1 (HCDR1) comprising SEQ ID NO:2; HCDR2 comprising SEQ ID NO:3; HCDR3 comprising SEQ ID NO:4; light chain complementarity determining region 1 (LCDR1) comprising SEQ ID NO:7; LCDR2 comprising SEQ ID NO:8; and LCDR3 comprising SEQ ID NO:10.

example 2

Attainment of Low-Density Lipoprotein Cholesterol Goals in Patients at High Cardiovascular Risk: Results from a Managed Care Population Study

[0134]Background: US guidelines support LDL-C goals based on patient's cardiovascular (CV) risk profile, however, little is known regarding real-world patterns of LDL-C goal attainment within specific high CV risk conditions.[0135]Methods: Patients from the Optumlnsight IMPACT Database (a large US multi-payer claims database) with an LDL-C measurement during July 2011 to June 2012 and high CV risk conditions were identified. Most recent LDL-C measurement was defined as the index date and high CV risk conditions were identified hierarchically during the pre-index period as follows: recent acute coronary syndrome (ACS, within 6 months pre-index date), coronary events (myocardial infarction, hospitalization for unstable angina, coronary revascularization), stroke, and peripheral vascular disease (PVD).[0136]Results: In total, 110,739 patients met ...

example 3

Low-Density Lipoprotein Cholesterol Goal Attainment and Lipid-Lowering Therapy in a High Cardiovascular Risk Managed Care Population

[0138]Background: While US guidelines support statins as first line therapy to reduce LDL-C, little is known regarding real-world patterns of LDL-C goal attainment with statins and other lipid-lowering therapies (LLTs).[0139]Methods: Patients from the OptumInsight IMPACT Database (a large US multi-payer claims database) with an LDL-C measurement during July 2011 to June 2012 and high risk CV conditions (coronary events (myocardial infarction, hospitalization for unstable angina, coronary revascularization), stroke, and peripheral vascular disease) were identified. LLT prescription was assessed as of most recent LDL-C measurement (index date) and categorized as high-potency statin (atorvastatin 40 / 80 mg, rosuvastatin 20 / 40 mg, simvastatin 80 mg), standard-potency statin (other statins), non-statin LLT (ezetimibe, niacin, fibrates, bile acid sequestrants)...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
total areaaaaaaaaaaa
densityaaaaaaaaaa
pharmaceutical compositionsaaaaaaaaaa
Login to View More

Abstract

The present invention provides methods and compositions for inhibiting atherosclerotic plaque formation in a subject. In certain embodiments, the methods of the present invention comprise selecting a subject who has, or is at risk of developing, atherosclerosis, and administering to the subject a pharmaceutical composition comprising a proprotein convertase subtilisin / kexin type 9 (PCSK9) inhibitor. In certain embodiments, this PCSK9 inhibitor is an anti-PCSK9 antibody, or antigen binding protein.

Description

RELATED APPLICATIONS[0001]This application claims the benefit of priority to U.S. Provisional Application No. 61 / 832,459, filed Jun. 7, 2013; European Patent Application No. 13305762.0, filed Jun. 7, 2013; U.S. Provisional Application No. 61 / 892,215, filed Oct. 17, 2013; European Patent Application No. 13306436.0, filed Oct. 18, 2013; U.S. Provisional Application No. 61 / 944,855, filed Feb. 26, 2014; and U.S. Provisional Application No. 62 / 002,508, filed May 23, 2014. The content of each of the aforementioned applications is hereby incorporated by reference in their entirety.FIELD OF THE INVENTION[0002]The present invention relates to the field of therapeutic treatments for atherosclerosis. More specifically, the invention relates to the administration of proprotein convertase subtilisin / kexin type 9 (PCSK9) inhibitors to inhibit atherosclerotic plaque formation in a subject.BACKGROUND[0003]Atherosclerosis represents the major cause of death and cardiovascular morbidity in the wester...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C07K16/40A61K31/4015A61K39/395A61K39/00C07K14/47
CPCC07K14/4703Y02A50/407C07K2317/565A61K39/3955C07K16/40C07K2317/76C07K2317/21A61K2039/505A61K31/4015A61P9/10A61P43/00Y02A50/30
Inventor SASIELA, WILLIAM J.GUSAROVA, VIKTORIAPEYMAN, ANUSCHSCHAEFER, HANS-LUDWIGSCHWAHN, UWE
Owner REGENERON PHARM INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com